Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023...

Related Keywords

Arizona ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Black Diamond ,Phoenix ,Mario Corso ,Mark Velleca ,Julie Seidel ,Drug Administration ,Nasdaq ,Exchange Commission ,Ivy Brain Tumor Center ,Development Expenses ,Company Masterkey ,International Conference On Molecular ,Diamond Therapeutics Inc ,Molecular Targets ,Diamond Therapeutics ,Chief Executive Officer ,Upcoming Milestones ,Cancer Therapeutics ,Board Mark Velleca ,Chief Executive ,Administrative Expenses ,Private Securities Litigation Reform Act ,Annual Report ,United States Securities ,Consolidated Balance Sheet Data ,Investor Relations ,Stern Investor ,Markets ,